Moderna's Surge May Be Short-Lived as Commercialization Remains Years Away

Moderna has experienced an incredible comeback over the past year, surging sixfold and by around 127% in recent weeks.

The biotech company's stock price rose sharply after it announced promising news for its pivot toward oncology, specifically a phase 3 trial of its Intismeran Autogene vaccine candidate combined with Merck's Keytruda in Stage IIB-IV melanoma patients.

While this development suggests Moderna can effectively employ its mRNA technology to develop cancer treatments, the extent of the company's latest rally was likely boosted by a short squeeze. Shares initially surged 175% on the news and have since pulled back.

The commercialization of these oncology MRNA products remains years away, with estimated 2026 revenue of just $2.1 billion and forecast losses of $8.55 per share this year.